REGN vs TRAK · P/E 14, rev $14.34B vs P/E 25, $167.9M cap
Regeneron Pharmaceuticals Inc (REGN) versus ReposiTrak (TRAK) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
ReposiTrak (TRAK) is a software - application company listed on NYSE.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
TRAK does not have a complete income-statement cache yet.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. TRAK currently screens at market cap $167.9M and trailing P/E 25.0.
Not investment advice. Open the REGN and TRAK stock pages for the full models.
Not investment advice.